Connect Biopharma is trading at $0.73, down 6.01% on November 5, alongside a broad-market selloff and biotech weakness.
- No new company-specific announcement explaining the November 5 decline was found; the latest company news located was September 30 clinical-trial data.
- Supplied sector context reported XBI down 5.19% during the regular session.
- Market coverage cited renewed AI-regulation concerns and technology-led risk aversion as pressures on equities.